Background
Myeloid leukemogenesis is driven by specific genetic mutations that uniquely contribute to oncogenic cellular phenotypes in the myeloid lineage [
1]. For many years, researchers have known of several key recurrent genetic aberrations (i.e., certain translocations or gene disruptions) that not only play important roles in the development of acute myeloid leukemia (AML) but also impact treatment responses and disease prognosis. Based on the functional categorization of these well-known mutations, it was proposed that genetic changes driving AML can be classified into two major groups:
class I aberrations that confer survival or proliferation advantages to myeloid blood cells and
class II aberrations that block the normal differentiation process of blood cells [
2‐
4]. Furthermore, the
two-hit theory stipulates that a combination of at least one class I aberration and one class II aberration is necessary for development of the AML phenotype [
5,
6]. In recent years, next-generation sequencing has facilitated the discovery of many other genetic anomalies in AML. While most of the newly identified genetic aberrations do not fit neatly into either of the two mutation classes, the combined genetic aberrations are thought to function via mechanisms that recapitulate leukemogenic effects on survival/proliferation and differentiation [
7]. Thus, the two-hit model is still considered to be a relevant paradigm of myeloid leukemogenesis, and it remains a useful framework for investigating how AML can result from orchestrated genetic aberrations [
1,
8].
Previously, Mullican et al. reported that two orphan receptor genes,
NR4A1 and
NR4A3, possess unexpected suppression functions in myeloid leukemogenesis. As such, concurrent abrogation of both nuclear receptors in mice results in the development of an AML-like phenotype [
9]. Even more importantly, the authors also showed that downregulation of each gene is a common feature in leukemic blasts from AML patients, irrespective of karyotype [
9]. While these findings suggest that the silencing of both genes plays a key role in myeloid leukemogenesis [
10], the impacts of individually downregulating
NR4A1 and
NR4A3 remain unclear. A few studies have linked
NR4A1 to apoptosis [
11‐
14], but the functional effects of
NR4A3 downregulation in myeloid cells and neoplasms are largely unknown. In the process of T-cell apoptosis,
NR4A3 was shown to be functionally redundant with
NR4A1 [
15,
16]. However, the genes may have non-overlapping functions in myeloid leukemogenesis. In support of this idea, the same group of researchers as those who produced the Mullican et al. study showed that knocking out asingle allele of either
NR4A1 or
NR4A13 gene alongside homozygous knockout of the other gene produced phenotypes consistent with mixed myelodysplastic/myeloproliferative neoplasms, revealing a gene-dose effect [
17]. Notably, the neoplastic phenotypes differed depending on which gene was fully knocked out, suggesting that the two genes are likely to act as cooperative rather than redundant suppressors of myeloid leukemogenesis [
17,
18].
Because the concurrent knock-out of
NR4A1 and
NR4A3 is sufficient to produce an AML-like phenotype in mice [
9], we speculated that the loss of both genes should satisfy the dual requirements of the two-hit theory of myeloid leukemogenesis.
NR4A1 is thought to function in cell apoptosis, so its downregulation would be expected to confer a survival advantage to myeloid cells (i.e., class I aberration). Thus,
NR4A3 downregulation might be expected to function in a complementary manner, as a class II aberration that impairs cell differentiation. Indeed, our clinical and experimental data in this study support this idea, leading us to conclude that
NR4A3 downregulation likely contributes to myeloid leukemogenesis by interfering with myeloid differentiation.
Methods
Patient cohorts and primary patient samples
The National Taiwan University Hospital (NTUH) cohort included 227 AML patients. The transcriptomes of bone marrow cells from these patients were profiled using the Illumina HumanHT-12 v4.0 Expression BeadChip platform (Illumina, San Diego, CA, USA), as described previously [
19] (Gene Expression Omnibus accession numbers GSE68469 and GSE71014). The expression data were log2 transformed and quantile normalized. The collection and analyses of patient samples were approved by the institutional review board of NTUH.
For the The Cancer Genome Atlas (TCGA) cohort, clinical and RNA-seq data from the TCGA-LAML cohort (
N = 151) were downloaded from the TCGA website (
https://portal.gdc.cancer.gov/). The gene expression data were normalized to Fragments Per Kilobase of transcript per Million mapped reads upper quartile (FPKM-UQ), and then a log2 transformation was applied.
The collection and use of archived marrow samples from patients with chronic myeloid leukemia (CML) and fresh blood samples from patients with acute promyelocytic leukemia (APL) were approved by the institutional review board of NTUH.
Cell lines
The K562 cell line was obtained from the Bioresource Collection and Research Center (BCRC) and maintained in IMDM (GIBCO, Life Technologies Corporation, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO, Life Technologies Corporation, NY, USA) and antibiotics (penicillin 100 U/ml, streptomycin 50 μg/ml; GIBCO, Life Technologies Corporation, NY, USA). NB4 cells were kindly provided by Prof. Wen-Chien Chou at National Taiwan University Hospital and were maintained in RPMI 1640 (GIBCO, Life Technologies Corporation, NY, USA) supplemented with 15% heat-inactivated FBS and antibiotics (penicillin 100 U/ml, streptomycin 50 μg/ml; GIBCO, Life Technologies Corporation, NY, USA). Both cell lines were grown in a 5% CO2 humidified atmosphere at 37 °C.
Cell differentiation
K562 and NB4 cell lines were treated with various differentiation-inducing agents. Megakaryocytic differentiation of K562 cells was assayed by real-time quantitative PCR to measure expression of the platelet-derived growth factor A (PDGFA) gene and by morphological examination of the cells after staining with Liu’s stain. Myelo-monocytic differentiation of NB4 cells was evaluated by morphological examination after Liu’s stain and flow cytometry (BD FACSverse™) for CD11b expression with PE-conjugated CD11b antibody (BD Biosciences Pharmingen, San Diego, CA, USA) or IgG1 isotype control antibody (eBioscience, Thermo Fisher Scientific Inc.). Flow cytometry data were analyzed with BD FACSuite software or FlowJo™ software for Windows, version 10 (Becton Dickinson, and Company, Ashland). To exclude dead cells, 7-AAD (BD Biosciences Phamingen) was added to facilitate the gating procedure.
RNA extraction and reverse transcription
Total RNA was extracted from the harvested cells using the NucleoSpin RNA mini Kit (Macherey–Nagel, GmbH & Co. KG, Germany). Residual genomic DNA was eliminated by treatment with RNase-free rDNase. Complementary DNA (cDNA) was generated by reverse transcription (RT) using the PrimeScript™ RT-PCR Kit (TAKARA Bio Inc., Japan).
Real-time quantitative polymerase chain reaction
A total of 100 ng of cDNA was added to a real-time quantitative polymerase chain reaction (RT-qPCR) mixture containing 2 × TaqMan PCR Master Mix (Roche Life Science, USA), primers, and fluorescent probes or SYBR Green (Applied Biosystems, Foster City, CA, USA). PCRs were performed using the Applied Biosystems 7900HT Real-Time PCR System and Applied Biosystems Sequence Detection Systems (SDS v2.2.2) software (Applied Biosystems, Foster City, CA, USA). The primer sequences for NR4A1 were forward: 5′-ACTTTGGGAAGGAAGATGCTG-3′, and reverse: 5′-TTCGGATGACCTCCAGAGAA-3′. To probe NR4A3, PDGFA, and ABL1 (housekeeping gene) expression, Taqman Gene Expression Assays were purchased (Hs00545007, Hs00964426, and Hs01104728, respectively; Applied Biosystems, Foster City, CA, USA). All gene expression experiments in patient samples were repeated twice.
Knockdown of NR4A3 expression
The SMARTpool ON-TARGETplus siRNA Set (catalog # LQ-003428–00) and the scrambled siRNA control used in K562 cells were purchased from Thermo Fisher Scientific (Lafayette, CO). The transfection was performed using the Neon™ Transfection System (catalog # MPK5000, Thermo Fisher Scientific., Lafayette, CO.) at settings of 1000 V, 50 ms, and 1 pulse. The sh-Luciferase control and two different shNr4A3 (D2-2 and E1-1) vectors used in NB4 cells were purchased from the RNAi Core of Academia Sinica, Taiwan. The shRNA target sequences were D2-2: GCAGACATACAGCTCGGAATA and E1-1: AGAAGATCAGACATTACTTAT. 293FT cells (Invitrogen, Life Technologies Corporation, NY, USA) were plated on 60-mm dishes and transfected with shNr4A3 or scrambled vector using Lipofectamine 2000 (Invitrogen, Life Technologies Corporation, NY, USA) to generate lentivirus. After transfection for 16–24 h, the medium was replaced with fresh complete medium containing 1% bovine serum albumin (BSA). Then, the supernatant was collected 24 and 48 h later. The supernatant, which contained lentivirus particles, was concentrated and cryopreserved at − 80 ℃. K562 or NB4 was seeded on 6-well plates, infected with concentrated lentivirus, and treated with puromycin for selection (Sigma-Aldrich). Total cell lysates were collected from K562 or NB4 cells to assess Nr4A3 gene expression. All data were derived from at least three independent experiments.
Statistical analysis
Data are represented as mean ± standard error of the mean (sem) unless otherwise specified. For measurements from clinical samples, statistical significance of differences between groups was determined by the Kruskal–Wallis test. For comparisons to the control group in cell culture experiments, paired Student’s t-test was used (two-tailed). p-values less than 0.05 were considered significant for all analyses.
Discussion
Our results in this study suggest that downregulation of
NR4A3 expression impairs myeloid cell differentiation, an effect that is non-overlapping with that of
NR4A1 downregulation. Combined with the known proliferation-promoting effects of
NR4A1 downregulation, the current findings can be incorporated into the classical two-hit leukemogenic framework to explain why concurrent abrogation of
NR4A1 and
NR4A3 in mice might result in AML-like phenotypes [
9,
17].
The mechanism by which
NR4A3 downregulation influences myeloid differentiation remains to be dissected. However, the action is expected to occur early in myeloid differentiation because induction of K562 cell differentiation into different lineages with various compounds yielded similar patterns of
NR4A3 upregulation. Furthermore, these observations suggest that the function of
NR4A3 is probably not associated with a single, specific differentiation program. In line with this notion, our preliminary RNA-seq data from NB4 cells before and after
NR4A3 knockdown showed positive enrichment of both myeloid and erythroid differentiation-related genes (Supplementary Fig.
2). Prior reports showed that
NR4A3 downregulation is a universal phenomenon in every subtype of AML, and in the current study, we show that
NR4A3 downregulation is also associated with the acute transformation of CML. Together, these findings lead us to speculate that downregulation of
NR4A3 is a universal phenomenon and a crucial player during myeloid leukemogenesis.
As yet, the molecular actions of NR4A3 protein are not well described, but there is some evidence that the protein may be maintained at low levels in the cell. In fact, we performed preliminary experiments overexpressing GFP-tagged NR4A3 protein in K562 and NB4 cells, but we ultimately failed to detect fluorescent signals in the cells. We also expressed the protein in 293 T cells but could only detect the signal in cells co-treated with the proteasome inhibitor bortezomib, suggesting that the overexpressed protein might be rapidly degraded (data not shown). In line with this idea, the initial report of
NR4A3 downregulation in myeloid leukemogenesis only included measurements of gene expression levels rather than protein levels [
9]. This is also true of studies probing
NR4A3 expression in eosinophils of patients with atopic dermatitis [
16,
27]. Based on the paucity of reports detecting endogenous protein with conventional immunohistochemistry or immunoblotting methods, it is possible that high turnover of NR4A3 might be an important regulatory mechanism of protein activity.
Because no mutations in
NR4A3 have been reported, the gene is probably not downregulated by loss-of-function mutations. However, it has been suggested that DNA methylation might contribute to
NR4A3 downregulation [
28]. In addition to this potential mechanism,
NR4A3 was found to be a downstream target of
RUNX1 [
29], a gene in which class II aberrations frequently occur in AML. As such,
NR4A3 downregulation may link the
RUNX1 class II mutation with its cellular effect of impaired differentiation. In the present study, we observed that
NR4A3 expression increases in APL patients after administration of ATRA-based differentiation therapy. Together, the findings imply that
NR4A3 expression might be regulated by multiple essential AML-associated genes, and it could serve as a common downstream effector of several different class II genetic aberrations.
The potential role of
NR4A3 downregulation in APL is especially intriguing. In the initial paper showing that coincident downregulation of
NR4A3 and
NR4A1 is sufficient to cause AML [
9], several APL cases were included in the group of samples used for clinical validations. Consistent with the other samples used for clinical validation, the APL samples had lower
NR4A3 expression levels than controls. Our experiments with NB4 cells (APL cell line with t(15;17)) and patient samples also showed that ATRA-induced differentiation consistently causes
NR4A3 upregulation. Furthermore, suppressing
NR4A3 upregulation in NB4 cells attenuated the ATRA-induced differentiation phenotype. These findings are compatible with the notion that downregulation of
NR4A3 is associated with impaired differentiation in APL. One possible mechanism that may link
NR4A3 downregulation with APL involves the fusion oncoprotein PML/RARα, which is the product of t(15;17). PML/RARα is known to enhance STAT3 expression [
30,
31], and STAT3 has been reported to epigenetically silence
NR4A3 expression in gastric cancer [
32]. Thus, PML/RARα might directly cause
NR4A3 downregulation and contribute to the development of APL. Further studies will be needed to assess this possibility.
While our data from ATRA-treated APL patients are limited to only three subjects, we saw that ATRA treatment predictably and consistently led to upregulation of
NR4A3 expression. This result suggests that differentiation treatment may upregulate
NR4A3, and it warrants future studies to examine the effect in large patient populations. Furthermore, this and our other findings suggest the possibility that
NR4A3-upregulating therapies may be applicable to myeloid leukemias. As such, restoration of
NR4A3 might be achieved using any of several identified compounds, such as histone deacetylase inhibitors, n-butylenephtalide, or palmitate [
33‐
39]. Moreover, NR4A3 agonists have also been identified, including 6-mercaptopurine or prostaglandin A2 [
40‐
43]. Thus, it may be possible to target either the gene expression level or activity of NR4A3 as a strategy for AML treatment.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.